ClinicalTrials.gg
TerminatedNCT02980874SAPPHIREUpdated Apr 14, 2021Results posted

Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO

A Phase 3 interventional study of suprachoroidal CLS-TA and suprachoroidal sham in Macular Edema and Retinal Vein Occlusion, sponsored by Clearside Biomedical, Inc.. Terminated at 110 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-04-14.

Sponsored by Clearside Biomedical, Inc. · Phase 3, Interventional, and Treatment

Why this study was terminated
Primary, 8-week efficacy endpoint not achieved. No additional benefit for subjects receiving a corticosteroid together with an intravitreal anti-VEGF agent.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
460
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies testing Triamcinolone Acetonide in Macular Edema — 1 open to participants now, 1 under way, none of them phase 3. Triamcinolone Acetonide · Macular Edema.

Enrollment
4th of 25
460 · median 75
Started
2017
the only one that year
Phase 3
8 of 26
none open now
Registered
18th of 26
by date
Lead sponsor
2 of 26
Clearside Biomedical, Inc.

Among the 26 studies testing Triamcinolone Acetonide in Macular Edema, this one is the 4th largest by enrollment of the 25 interventional ones that give a count, is the only one that started in 2017, is one of 8 in phase 3, and was the 18th registered.

Macular Edema

758 studies on the registry are indexed under Macular Edema; 65 are open to participants now.

Browse Macular Edema studies →

Open to participants now

1 of the 26 studies testing Triamcinolone Acetonide in Macular Edema is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About Triamcinolone Acetonide

Triamcinolone Acetonide: first FDA approval 1958 (TRIAMCINOLONE ACETONIDE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies testing Triamcinolone Acetonide in Macular Edema, or all of them as a file.
02

Study summary

This is a Phase 3, multicenter, randomized, masked, controlled, parallel group study of 12 months duration in treatment naïve subjects with RVO.

Read the detailed description

A randomized, masked, controlled trial to study the safety and efficacy of suprachoroidal CLS-TA in conjunction with intravitreal aflibercept in subjects with retinal vein occlusion

03

Conditions studied

  • Macular Edema
  • Retinal Vein Occlusion

Keywords

  • RVO
  • ME
  • Central Subfield Thickness
  • OCT
  • Optical Coherence Tomography
  • Cystoid Macular Edema
  • Subretinal Fluid
  • Eylea
  • Aflibercept
  • Anti-VEGF
  • Suprachoroidal
  • Triamcinolone acetonide
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has a clinical diagnosis of RVO in the study eye
  • Has a CST of ≥ 300 µm in the study eye
  • Has an ETDRS BCVA score of ≥ 20 letters read and ≤ 70 letters read in the study eye;
  • Is naïve to local pharmacologic treatment for RVO in the study eye;

Exclusion criteria

Exclusion Criteria:

  • Any active ocular disease or infection in the study eye other than RVO
  • History of glaucoma, intraocular pressure > 21 mmHg or ocular hypertension requiring more than one medication
  • Any uncontrolled systemic disease that, in the opinion of the Investigator, would preclude participation in the study
  • Any evidence of neovascularization in the study eye
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
460 participants (actual)

Study arms

  • Experimental
    Active

    IVT aflibercept (2 mg/0.05 mL) + CLS-TA (4 mg/100 µL) SC injections

    Drug: suprachoroidal CLS-TA · Drug: IVT aflibercept

  • Active comparator
    Control

    IVT aflibercept (2 mg/0.05 mL) + sham SC procedure

    Drug: suprachoroidal sham · Drug: IVT aflibercept

Interventions

  • suprachoroidal injection of CLS-TA

    Also known as: Triamcinolone acetonide

  • Drugsuprachoroidal sham

    suprachoroidal sham procedure

  • 2 mg intravitreal injection of aflibercept

    Also known as: Aflibercept

06

What researchers measure

Primary outcomes

  1. Proportion of Subjects Demonstrating ≥ 15 Letter Improvement From Baseline in Early Treatment of Diabetic Retinopathy Study (ETDRS)

    Best corrected visual acuity (BCVA) refers to the measurement of the best possible vision that can be achieved following refraction or correction. BCVA was assessed following the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol and was measured in the number of letters read correctly on an ETDRS eye chart. An increase from the pre-treatment state in BCVA of 15 letters or more represents a clinically meaningful improvement.

    Time frame: 2 months

Secondary outcomes

  1. Mean Change From Baseline in Best Corrected Visual Acuity

    Best corrected visual acuity (BCVA) refers to the measurement of the best possible vision that can be achieved following refraction or correction. BCVA was assessed following the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol and was measured in the number of letters read correctly on an ETDRS eye chart. A positive change from baseline value represents an improvement in vision.

    Time frame: 6 months

  2. Mean Change From Baseline in Central Subfield Thickness

    Central subfield thickness (CST) is a diagnostic measurement used in identifying the presence of edema in the circular area 1 mm in diameter centered around the fovea. CST was measured using spectral domain optical coherence tomography (SD-OCT). A masked reading center graded the SD-OCT digital images. A negative change from baseline value represents a reduction in macular edema.

    Time frame: 6 months

07

Results

Posted Apr 14, 2021
Limitations and caveats
Due to the early termination of the trial by sponsor all planned study visits were not completed by all treated subjects; therefore, all planned data was not collected.

Participant flow

Participant flow — Overall Study
MilestoneActiveControl
Started231229
Completed128127
Not completed103102
Withdrew: Adverse event27
Withdrew: Withdrawal by subject72
Withdrew: Lost to follow-up55
Withdrew: Includes premature discontinuation due to study termination.8888
Withdrew: Unknown study completion status10

Outcome measures

PrimaryProportion of Subjects Demonstrating ≥ 15 Letter Improvement From Baseline in Early Treatment of Diabetic Retinopathy Study (ETDRS)

Best corrected visual acuity (BCVA) refers to the measurement of the best possible vision that can be achieved following refraction or correction. BCVA was assessed following the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol and was measured in the number of letters read correctly on an ETDRS eye chart. An increase from the pre-treatment state in BCVA of 15 letters or more represents a clinically meaningful improvement.

Time frame:
2 months
Reported as:
Count of participants · Participants
Proportion of Subjects Demonstrating ≥ 15 Letter Improvement From Baseline in Early Treatment of Diabetic Retinopathy Study (ETDRS)
ParticipantsActiveControl
Proportion of Subjects Demonstrating ≥ 15 Letter Improvement From Baseline in Early Treatment of Diabetic Retinopathy Study (ETDRS)114127
Statistical analysis
  • Active vs Control · Cochran-Mantel-Haenszel · p = 0.187 (The a priori threshold for statistical significance was 0.050. Prior to evaluating the results of the CMH test, a Breslow-Day test with Tarone's adjustment was conducted to confirm the homogeneity of the odds ratios between RVO strata.) · Difference in percentages: -6.1 · 95% CI -15.2 to 3.0Estimated value was calculated as the percentage of subjects in the Active arm meeting the primary endpoint minus the percentage of subjects in the Control arm meeting the primary endpoint.
SecondaryMean Change From Baseline in Best Corrected Visual Acuity

Best corrected visual acuity (BCVA) refers to the measurement of the best possible vision that can be achieved following refraction or correction. BCVA was assessed following the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol and was measured in the number of letters read correctly on an ETDRS eye chart. A positive change from baseline value represents an improvement in vision.

Time frame:
6 months
Reported as:
Least squares mean · Letters
Mean Change From Baseline in Best Corrected Visual Acuity
LettersActiveControl
Mean Change From Baseline in Best Corrected Visual Acuity15.5 ± 0.8520.5 ± 0.85
SecondaryMean Change From Baseline in Central Subfield Thickness

Central subfield thickness (CST) is a diagnostic measurement used in identifying the presence of edema in the circular area 1 mm in diameter centered around the fovea. CST was measured using spectral domain optical coherence tomography (SD-OCT). A masked reading center graded the SD-OCT digital images. A negative change from baseline value represents a reduction in macular edema.

Time frame:
6 months
Reported as:
Least squares mean · Microns
Mean Change From Baseline in Central Subfield Thickness
MicronsActiveControl
Mean Change From Baseline in Central Subfield Thickness-354.3 ± 8.01-416.2 ± 8.05

Adverse events

Collected over Adverse events were collected over 48 weeks of follow-up.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Active0/231 (0%)25/231 (10.8%)128/231 (55.4%)
Control0/229 (0%)28/229 (12.2%)83/229 (36.2%)
Most frequent serious events
Showing 10 of 68
Most frequent serious events
EventActiveControl
AnaemiaBlood and lymphatic system disorders0/2313/229
Transient ischaemic attackNervous system disorders0/2313/229
Intraocular pressure increasedInvestigations3/2310/229
Coronary artery diseaseCardiac disorders0/2312/229
Myocardial infarctionCardiac disorders0/2312/229
Chest painGeneral disorders1/2312/229
Atrial fibrillationCardiac disorders2/2311/229
Visual acuity reducedEye disorders2/2310/229
Urinary tract infectionInfections and infestations2/2310/229
HyponatraemiaMetabolism and nutrition disorders2/2310/229
Most frequent other events
Most frequent other events
EventActiveControl
Conjunctival haemorrhageEye disorders42/23128/229
Intraocular pressure increasedInvestigations33/2319/229
CataractEye disorders21/2319/229
Cataract subcapsularEye disorders20/2313/229
Eye painEye disorders20/23111/229
Visual acuity reducedEye disorders16/2316/229
HypertensionVascular disorders15/23115/229
Macular oedemaEye disorders8/23113/229
NasopharyngitisInfections and infestations9/23113/229
Vitreous detachmentEye disorders13/2319/229

Baseline characteristics

The Safety population included all randomly assigned subjects who were administered at least one dose of the study drug.

Age, Categorical
Age, Categorical(Participants)ActiveControlTotal
<=18 years000
Between 18 and 65 years89107196
>=65 years142122264
Age, Continuous
Age, Continuous(Years)ActiveControlTotal
Mean66.4 ± 12.3164.9 ± 12.4265.7 ± 12.37
Sex: Female, Male
Sex: Female, Male(Participants)ActiveControlTotal
Female97105202
Male134124258
Race (NIH/OMB)
Race (NIH/OMB)(Participants)ActiveControlTotal
American Indian or Alaska Native202
Asian334073
Native Hawaiian or Other Pacific Islander101
Black or African American101222
White181177358
More than one race101
Unknown or Not Reported303
Region of Enrollment
Region of Enrollment(Participants)ActiveControlTotal
Hungary617
United States182183365
Philippines033
United Kingdom426
Portugal325
India131932
Spain325
Canada235
Taiwan213
Denmark213
Poland5510
Slovakia011
Australia9615
Type of Retinal Vein Occlusion
Type of Retinal Vein Occlusion(Participants)ActiveControlTotal
Branch retinal vein occlusion124124248
Central retinal vein occlusion107105212
08

Study locations

110 sites
  • Associated Retina Consultants, Ltd.
    Peoria, Arizona 85381, United States
  • Retinal Consultants of Arizona and Retinal Research Institute
    Phoenix, Arizona 85014-2709, United States
  • Arizona Retina and Vitreous Consultants
    Phoenix, Arizona 85021, United States
  • Associated Retina Consultants, Ltd.
    Phoenix, Arizona 85381, United States
  • Retina Centers P.C.
    Tucson, Arizona 85704, United States
  • California Retina Research Consultants
    Bakersfield, California 93309, United States
  • Retina Vitreous Medical Group Clinical Research
    Beverly Hills, California 90211-1841, United States
  • Atlantis Eyecare
    Huntington Beach, California 92647, United States
  • Jacobs Retina Center at the Shiley Eye Institute, UCSD
    La Jolla, California 92093, United States
  • Northern California Retina Vitreous Associates
    Mountain View, California 94040, United States
  • East Bay Retina Consultants Inc.
    Oakland, California 95409, United States
  • Southern California Desert Retina Consultants
    Palm Desert, California 92211, United States
  • Retina Institute of California
    Palm Desert, California 92260, United States
  • Retina Consultants San Diego
    Poway, California 92064-2526, United States
  • Orange County Retina Medical Group
    Santa Ana, California 92705, United States
  • California Retina Consultants CRC
    Santa Barbara, California 93103, United States
  • Bay Area Retina Associates
    Walnut Creek, California 94599, United States
  • Colorado Retina Associates
    Golden, Colorado 80401, United States
  • New England Retina Associates
    Hamden, Connecticut 06518, United States
  • MedEye Associates
    Miami, Florida 33143-5188, United States
  • Retina Specialty Institute
    Pensacola, Florida 32503, United States
  • Retina Vitreous Associates of Florida
    Saint Petersburg, Florida 33711, United States
  • Sarasota Retina Institute
    Sarasota, Florida 34239, United States
  • Center for Retina and Macular Disease
    Winter Haven, Florida 33880, United States
  • Emory Eye Center
    Atlanta, Georgia 30322, United States
  • Southeast Retina Center, PC
    Augusta, Georgia 30909, United States
  • Marietta Eye Clinic
    Marietta, Georgia 30060, United States
  • Retina Consultants of Hawaii
    'Aiea, Hawaii 96701, United States
  • Illinois Eye and Ear Infirmary, UIC
    Chicago, Illinois 60612, United States
  • Illinois Retina Associates
    Chicago, Illinois 60657, United States
  • Carle Foundation Hospital
    Urbana, Illinois 61801, United States
  • Midwest Eye Institute
    Indianapolis, Indiana 46290, United States
  • Retina Associates, PA
    Shawnee Mission, Kansas 66204, United States
  • Retina and Vitrous Associates of Kentucky
    Lexington, Kentucky 40509, United States
  • Wilmer Eye Institute John Hopkins University
    Baltimore, Maryland 21287-0005, United States
  • Cumberland Valley Retina Consultants
    Hagerstown, Maryland 21740-5940, United States
  • The Retina Institute
    Saint Louis, Missouri 63128, United States
  • Retina Associates of NJ
    Teaneck, New Jersey 07666, United States
  • Western Carolina Retinal Associates, PA
    Asheville, North Carolina 28803, United States
  • Cincinnati Eye Institute
    Cincinnati, Ohio 45242, United States
  • Cleveland Clinic Foundation/Cole Eye Institute
    Cleveland, Ohio 44195, United States
  • Oregon Retina Institute
    Medford, Oregon 97504, United States
  • Casey Eye Institute/Oregon Health & Science University
    Portland, Oregon 97239, United States
  • Eye Care Specialists
    Kingston, Pennsylvania 18704, United States
  • Wills Eye Hospital
    Philadelphia, Pennsylvania 19107, United States
  • Black Hills Regional Eye Institute
    Rapid City, South Dakota 57701-7374, United States
  • Retina Research Institute of Texas
    Abilene, Texas 79606-1224, United States
  • Texas Retina Associates-Arlington
    Arlington, Texas 76012-2505, United States
  • Austin Retina Associates
    Austin, Texas 78705, United States
  • Texas Retina Associates
    Dallas, Texas 75231, United States
  • Retina Consultants of Houston
    Houston, Texas 77030, United States
  • Valley Retina Institute
    McAllen, Texas 78503, United States
  • Medical Center Ophthalmology Associates
    San Antonio, Texas 78240-1502, United States
  • Retina Consultants of Houston
    The Woodlands, Texas 77384, United States
  • University of Utah HSC - John A. Moran Eye Center
    Salt Lake City, Utah 84132, United States
  • Retina Institute of Virginia
    Richmond, Virginia 23235, United States
  • Virginia Retina Center
    Warrenton, Virginia 20186, United States
  • University of Wisconsin-Madison
    Madison, Wisconsin 53705, United States
  • Strathfield Retina Clinic
    Strathfield, New South Wales 2135, Australia
  • Save Site Institute, University of Sydney, Sydney Eye Hospital
    Sydney, New South Wales 2000, Australia
  • Sydney Retina Clinic and Day Surgery
    Sydney, New South Wales 2000, Australia
  • Marsden Eye Specialists
    Sydney, New South Wales 2150, Australia
  • The Royal Victorian Eye and Ear Hospital
    East Melbourne, Victoria 3002, Australia
  • Specialist Eye Group
    Melbourne, Victoria 3150, Australia
  • University of Graz-Department of Ophthalmology
    Graz, Austria
  • Kepler University Hospital
    Linz, Austria
  • UBC/VGH Eye Care Centre
    Vancouver, British Columbia V5Z 3N9, Canada
  • St. Joseph's Health Care London, Ivey Eye Institute
    London, Ontario N6A 4V2, Canada
  • University of Ottawa Eye Institute
    Ottawa, Ontario K1H 8L6, Canada
  • Institut de l'oeil des Laurentides
    Boisbriand, Quebec J7H 1S6, Canada
  • CIUSSS de l'Est-de-l'Ile-de-Montreal. Hospital Maisonneuve-Rosemont, Comite d'ethique de la recherche
    Montréal, Quebec H1T 2M4, Canada
  • Rigshospitalet
    Glostrup, Denmark
  • Dept. of Ophthalmology, Sjællands Universitetshospital, Roskilde
    Roskilde, Denmark
  • Semmelweis Egyetem, Szemeszeti Klinika
    Budapest, 1083, Hungary
  • Bajcsy-Zsilinszky Korhaz es Rendelointezet, Szemeszeti Osztaly
    Budapest, 1106, Hungary
  • Magyar Honvedseg Egeszsegugyi Kozpont
    Budapest, 1162, Hungary
  • Budapest Retina Associates
    Budapest, Hungary
  • Debreceni Egyetem Klinikai Kozpont, Szemklinika
    Debrecen, 4032, Hungary
  • Ganglion Orvosi Kozpont
    Pecs, 7621, Hungary
  • M&J Western Regional Institute of Ophthalmology
    Ahmedabad, Gujarat 380016, India
  • T.N. Medical College and B.Y.L. Nair Charitable Hospital
    Mumbai, Maharashtra 400008, India
  • Department of Medical Ophthalmology, Retina & Uvea
    Delhi, New Delhi 110029, India
  • Aravind Eye Hospitals & Postgraduate Institute of Ophthalmology
    Madurai, Tamil Nadu 625020, India
  • Smt. Kanuri Santhamma Centre for Vitreo Retinal Diseases
    Hyderabad, Telangana 500034, India
  • Disha Eye Hospital Private Limited
    Kolkata, West Bengal 700120, India
  • Bnai Zion Medical Center
    Haifa, 3104802, Israel
  • ASST Fatebenefratelli Sacco - P.O.L., University of Milan, Dep. of Ophthalmology
    Milan, 20157, Italy
  • Cebu Doctor's University Hospital
    Cebu City, 6000, Philippines
  • Peregrine Eye & Laser Institute
    Makati City, 1209, Philippines
  • The Medical City
    Pasig City, 1600, Philippines
  • Oftalmika sp. z o. o.
    Bydgoszcz, 85-631, Poland
  • Optimum Profesorskie Centrum Okulistyki
    Gdansk, 80-809, Poland
  • Uniwersytet Medyczny w Lublinie
    Lublin, 20-079, Poland
  • Centrum Diagnostyki i Mikrochirurgii Oka Lens
    Olsztyn, 10-424, Poland
  • Centro Clinico Academico Braga - 2CA-Braga
    Braga, 4710-243, Portugal
  • Centro Hospitalar e Universitario de Coimbra, E.P.E.
    Coimbra, 3000-075, Portugal
  • Centro Hospitalar de Sao Joao, E.P.E.
    Porto, 4200-319, Portugal
  • Fakultna nemocnica s poliklinikou Zilina
    Žilina, 01207, Slovakia
  • Instituto Cinico Quirurgico de Oftalmologia
    Bilbao, Vizcaya 48006, Spain
  • Hospital General de Catalunya
    Barcelona, Spain

Showing the first 100 of 110 sites across 16 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2017 to primary completion in Dec 2018, 22 months.

Results were first posted in Apr 2021, 2 years 4 months after primary completion. A results delay was requested in Dec 2019.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 30, 2016
First posted
Dec 2, 2016
StartActual
Jan 31, 2017
Primary completionActual
Dec 10, 2018
CompletionActual
Dec 10, 2018
Results delay requested
Dec 13, 2019
Results first posted
Apr 14, 2021
Last update
Apr 14, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 14, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02980874
Lead sponsor
Clearside Biomedical, Inc.
Responsible party
Sponsor
First posted
Dec 2, 2016
Start date
Jan 31, 2017
Primary completion
Dec 10, 2018
Completion
Dec 10, 2018
Results posted
Apr 14, 2021
Last update
Apr 14, 2021

Study contacts

Thomas Ciulla, MD MBA
study director · Clearside Biomedical, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Triamcinolone Acetonide

Start the discussion